September 9, 2019– Congress is back in town this week after the end of its August recess, and lawmakers are gearing up for a busy fall with a major focus on how to slow down ever-increasing drug prices. The cost of prescription drugs is on the minds of members from both parties in Congress as well as members of the Trump administration. Before they left town, two Senate … [Read more...]
Drug Industry Consultant Paints Incomplete Picture of 340B
May 14, 2019– Drug-industry consultant Adam Fein has released his annual analysis of the 340B program, painting an incomplete picture of the size and scope of the program. Fein claims in his Drug Channels blog that the 340B program “accounts for at least 7-to-8 percent of the total U.S. drug market […] yet hospitals’ charity care has dropped amid 340B program’s growth.” Not … [Read more...]
Drug companies answer scrutiny with more lobbying dollars
May 2, 2019— With its pricing practices under a congressional microscope, the pharmaceutical industry’s top trade group spent nearly $10 million on lobbying expenditures in the first three months of this year. That figure is on top of additional millions spent by some of the individual companies that have received the most attention recently in the drug pricing … [Read more...]